Compare TENB & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENB | TSHA |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2018 | 2020 |
| Metric | TENB | TSHA |
|---|---|---|
| Price | $25.43 | $5.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | ★ $31.69 | $11.63 |
| AVG Volume (30 Days) | ★ 3.3M | 2.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.23 | ★ 5.56 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $999,405,000.00 | $9,773,000.00 |
| Revenue This Year | $9.37 | N/A |
| Revenue Next Year | $7.04 | $1,152.42 |
| P/E Ratio | $2,522.00 | ★ N/A |
| Revenue Growth | 11.04 | ★ 17.28 |
| 52 Week Low | $15.73 | $2.25 |
| 52 Week High | $35.69 | $7.30 |
| Indicator | TENB | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 75.51 | 40.92 |
| Support Level | $22.03 | $5.37 |
| Resistance Level | $30.79 | $6.02 |
| Average True Range (ATR) | 1.23 | 0.43 |
| MACD | 0.40 | -0.23 |
| Stochastic Oscillator | 90.77 | 13.38 |
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.